Epidemiology and survival outcome of breast cancer in a nationwide study

Breast cancer is among the most prevalent cancers in Taiwan. The National Health Insurance database was used to identify patients with breast cancer and estimate the yearly prevalence and incidence of breast cancer between 1997 and 2013. Joinpoint regression analysis was used for the annual percentage change of incidence, prevalence, and survival outcome. Among 12,181,919 female beneficiaries in 2013, the prevalence was 834.37 per 100,000 persons (95% confidence interval, 829.28–839.45) and the incidence was 93.00 per 100,000 person-year (95% confidence interval, 91.27–94.73). The average annual percentage change of the age-standardized breast cancer incidence was 3.5 per 100,000 person-years (3.1–3.8; P < 0.05), suggesting an increase in breast cancer incidence over the study period. The 5-year mortality rate was 4.5% in 1997 and 4.4% in 2008. The 5-year mortality rate among patients with Charlson comorbidity index > 1 was 39.1% (19.2%–59.1%) in 1997 and 21.1% (15.7%-32.0%) in 2008, with an annual percentage change of –0.8 (–1.3 to 2.9), suggesting that the mortality rate was gradually decreasing in patients with comorbidities. In conclusion, 1 in 120 women in Taiwan has breast cancer and the incidence is rising, while the annual percentage change of breast cancer prevalence is decreasing. The mortality rate of breast cancer was essentially stable, but the 1-year, 2-year, and 5-year mortality rates in people with Charlson comorbidity index > 1 were declined.

[1]  Wei-Cheng Lo,et al.  Incidence and survival of adult cancer patients in Taiwan, 2002-2012. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[3]  M. Kerin,et al.  Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype , 2012, Breast Cancer Research and Treatment.

[4]  P. Rosenberg,et al.  Female breast cancer incidence among Asian and Western populations: more similar than expected. , 2015, Journal of the National Cancer Institute.

[5]  M. Fernö,et al.  Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications , 2015, Oncotarget.

[6]  M. Lai,et al.  Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. , 2014, The oncologist.

[7]  Ding Ma,et al.  Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer , 2016, Oncotarget.

[8]  Chien-Jen Chen,et al.  Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan , 2010, Cancer science.

[9]  R. Bhargava,et al.  Prognostic factors in male breast cancer: a population-based study , 2016, Breast Cancer Research and Treatment.

[10]  Ellen Warner,et al.  Clinical practice. Breast-cancer screening. , 2011, The New England journal of medicine.

[11]  D. Noh,et al.  Validation of Risk Assessment Models for Predicting the Incidence of Breast Cancer in Korean Women , 2014, Journal of breast cancer.

[12]  I. Fentiman.  Male breast cancer is not congruent with the female disease. , 2016, Critical reviews in oncology/hematology.

[13]  W. Chau,et al.  Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer in Hong Kong, Southern China: 1997–2006 , 2014, Annals of Surgical Oncology.

[14]  M. Lai,et al.  Cancer trends in Taiwan. , 2010, Japanese journal of clinical oncology.

[15]  Patrick Neven,et al.  Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer , 2015 .

[16]  J. Lee,et al.  Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database , 2016, Medicine.

[17]  A. Jemal,et al.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women , 2016, CA: a cancer journal for clinicians.

[18]  King-Jen Chang,et al.  Population-Based Breast Cancer Screening With Risk-Based and Universal Mammography Screening Compared With Clinical Breast Examination: A Propensity Score Analysis of 1 429 890 Taiwanese Women. , 2016, JAMA oncology.

[19]  Barbara L. Smith,et al.  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Marvin Zelen,et al.  Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.

[21]  M. Buyse,et al.  Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[22]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[23]  Kelvin K. W. Chan,et al.  Associations among socioeconomic status, patterns of care, and outcomes in breast cancer patients in a universal health care system: Ontario's experience , 2016, Cancer.

[24]  C. Hsiung,et al.  Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan , 2015, PloS one.

[25]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[26]  C. Fox,et al.  Breast-cancer screening. , 1979, Lancet.

[27]  H. Gilbert Welch,et al.  Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence , 2013 .

[28]  A. Wolff,et al.  Treatment of HER2-positive breast cancer. , 2014, Breast.

[29]  Keda Yu,et al.  Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study , 2015, Oncotarget.

[30]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Boffetta,et al.  Features of breast cancer in developing countries, examples from North-Africa. , 2014, European journal of cancer.

[32]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[33]  Kee Seng Chia,et al.  Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women , 2012, Breast Cancer Research.

[34]  Z. Hall.  Cancer , 1906, The Hospital.

[35]  J. J. van der Hoeven,et al.  [70-Gene signature as an aid to treatment decisions in early-stage breast cancer]. , 2017, Nederlands tijdschrift voor geneeskunde.

[36]  A. Ludwin,et al.  Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980–2013): an analysis of population-based data in relation to socioeconomic changes , 2016, OncoTargets and therapy.

[37]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.